142 related articles for article (PubMed ID: 9052766)
1. Proteinase inhibition in invasive cancer therapy: four control levels of matrix degradation.
Opdenakker G; Paemen L; Norga K; Masure S
Int J Cancer; 1997 Mar; 70(5):628-30. PubMed ID: 9052766
[No Abstract] [Full Text] [Related]
2. Cancer. Proteases--invasion and more.
Edwards DR; Murphy G
Nature; 1998 Aug; 394(6693):527-8. PubMed ID: 9707109
[No Abstract] [Full Text] [Related]
3. Protease inhibitors: role and potential therapeutic use in human cancer.
DeClerck YA; Imren S
Eur J Cancer; 1994; 30A(14):2170-80. PubMed ID: 7857719
[TBL] [Abstract][Full Text] [Related]
4. The potential for proteinase inhibition in cancer treatment.
Dodwell DJ; Howell A
Cancer Treat Rev; 1993 Jul; 19(3):283-96. PubMed ID: 8334678
[No Abstract] [Full Text] [Related]
5. Clinical studies with matrix metalloproteinase inhibitors.
Brown PD
APMIS; 1999 Jan; 107(1):174-80. PubMed ID: 10190295
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical studies of MMP inhibitors in cancer.
Drummond AH; Beckett P; Brown PD; Bone EA; Davidson AH; Galloway WA; Gearing AJ; Huxley P; Laber D; McCourt M; Whittaker M; Wood LM; Wright A
Ann N Y Acad Sci; 1999 Jun; 878():228-35. PubMed ID: 10415734
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases. Novel targets for directed cancer therapy.
Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibitors: present achievements and future prospects.
Denis LJ; Verweij J
Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Rudek MA; Venitz J; Figg WD
Pharmacotherapy; 2002 Jun; 22(6):705-20. PubMed ID: 12066962
[TBL] [Abstract][Full Text] [Related]
10. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
11. Experimental models to identify antimetastatic drugs: are we there yet? A position paper.
Zucker S
Ann N Y Acad Sci; 1999 Jun; 878():208-11. PubMed ID: 10415732
[No Abstract] [Full Text] [Related]
12. BAY12-9566. BAY 12 9566, BAY12 9566.
Drugs R D; 1999 Feb; 1(2):142-3. PubMed ID: 10566009
[No Abstract] [Full Text] [Related]
13. Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor.
Matsuoka T; Yashiro M; Sawada T; Ishikawa T; Ohira M; Chung KH
Anticancer Res; 2000; 20(6B):4331-8. PubMed ID: 11205267
[TBL] [Abstract][Full Text] [Related]
14. AG 3340.
Drugs R D; 1999 Feb; 1(2):137-8. PubMed ID: 10566007
[No Abstract] [Full Text] [Related]
15. Matrix metalloproteinase inhibitors as anticancer agents.
Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
[TBL] [Abstract][Full Text] [Related]
16. [Proteases in malignant tumors. Their significance for pathogenesis and possible therapeutic consequences].
Fröhlich E
Dtsch Med Wochenschr; 2004 Feb; 129(8):391-5. PubMed ID: 14961448
[No Abstract] [Full Text] [Related]
17. [The metalloproteinases in cancer].
Noël A; Foidart JM
Bull Mem Acad R Med Belg; 2005; 160(10-12):417-24; discussion 424-5. PubMed ID: 16768246
[TBL] [Abstract][Full Text] [Related]
18. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
Talbot DC; Brown PD
Eur J Cancer; 1996 Dec; 32A(14):2528-33. PubMed ID: 9059343
[No Abstract] [Full Text] [Related]
19. Marimastat. BB 2516, TA 2516.
Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
[No Abstract] [Full Text] [Related]
20. Proteolytic degradation of extracellular matrix in tumor invasion.
Tryggvason K; Höyhtyä M; Salo T
Biochim Biophys Acta; 1987 Nov; 907(3):191-217. PubMed ID: 2823896
[No Abstract] [Full Text] [Related]
[Next] [New Search]
